- In an interview with Reuters, Genmab A/S (OTCPK:GNMSF)(OTCPK:GMXAY) chief executive Jan van de Winkel says Darzalex (daratumumab) could achieve peak sales of $9B which could stretch to $13B if the monoclonal antibody works in solid tumors.
- Darzalex, exclusively developed by J&J's (JNJ -0.1%) Janssen Biotech, was first approved in the U.S. in November 2015 and in the EU in May 2016 to treat multiple myeloma. Janssen obtained the rights to the CD38 inhibitor via an August 2012 agreement with Genmab.